Navigation Links
Monoclonal Antibodies Market Dealmaking in Biopharma Industry Analyzed in New Research Report at ReportsnReports.com
Date:6/6/2013

Dallas, Texas (PRWEB) June 06, 2013

Monoclonal Antibodies Partnering Terms & Agreements are intended to provide the reader with an in-depth understanding and access to monoclonal antibodies trends and structure of deals entered into by leading companies worldwide.

Monoclonal Antibodies Partnering Terms & Agreements (http://www.reportsnreports.com/reports/250370-monoclonal-antibodies-partnering-terms-and-agreements.html) includes:

  •     Trends in monoclonal antibodies dealmaking in the Biopharma industry since 2007
  •     Analysis of monoclonal antibodies deal structure
  •     Access to headline, upfront, milestone and royalty data
  •     Access to over 700 monoclonal antibodies deal records
  •     The leading monoclonal antibodies deals by value since 2007
  •     Includes chimeric mAb, humanized mAb, human mAb and murine mAb deals and alliances since 2007

In Monoclonal Antibodies Partnering Terms & Agreements, the available deals are listed by:

  •     Company A-Z
  •     Headline value
  •     Stage of development at signing
  •     Deal component type
  •     Monoclonal antibodies type

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. The Monoclonal Antibodies Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the monoclonal antibodies partnering deals and agreements entered into by the world's leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter monoclonal antibody partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors monoclonal antibody technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest monoclonal antibody deals announced in the healthcare sectors.

Understanding the flexibility of a prospective partner’s negotiated deals' terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all monoclonal antibody partnering deals announced since 2007 including financial terms where available including over 700 links to online deal records of actual biomarker partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

For example, analyzing actual company deals and agreements allows assessment of the following:

  •     What is actually granted by the agreement to the partner company?
  •     What exclusivity is granted?
  •     What are the precise rights granted or optioned?
  •     What is the payment structure for the deal?
  •     How are sales and payments audited?
  •     What is the deal term?
  •     How are the key terms of the agreement defined?
  •     How are IPRs handled and owned?
  •     Who is responsible for commercialization?
  •     Who is responsible for development, supply, and manufacture?
  •     How is confidentiality and publication managed?
  •     How are disputes to be resolved?
  •     Under what conditions can the deal be terminated?
  •     What happens when there is a change of ownership?
  •     What sublicensing and subcontracting provisions have been agreed?
  •     Which boilerplate clauses does the company insist upon?
  •     Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  •     Which jurisdiction does the company insist upon for agreement law?

Buy a copy of report @ http://www.reportsnreports.com/purchase.aspx?name=250370.

Monoclonal Antibodies Partnering Terms & Agreements provides the reader with the following key benefits:

  •     In-depth understanding of monoclonal antibodies deal trends since 2007
  •     Access to headline, upfront, milestone and royalty data
  •     Acces to the structure of monoclonal antibodies agreements with numerous real life case studies
  •     Comprehensive access to over 700 actual monoclonal antibodies deals entered into by the world’s biopharma companies
  •     Insight into the terms included in a monoclonal antibodies agreement, together with real world clause examples
  •     Understand the key deal terms companies have agreed in previous deals        
  •     Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Explore more reports on Pharmaceuticals Market @ http://www.reportsnreports.com/market-research/pharmaceuticals/.

About US:

ReportsnReports.com is an online market research reports (http://www.reportsnreports.com/) library of 200,000+ reports and in-depth studies of 5000+ micro markets. Our database includes reports by leading publishers from across the globe.

Read the full story at http://www.prweb.com/releases/monoclonal-antibodies/market-dealmaking/prweb10808044.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Monoclonal Antibodies Market - New Industry Research Report is Now Available for Pre-Order at Transparency Market Research
2. Monoclonal antibody appears effective and safe in asthma Phase IIa trial
3. New monoclonal antibody inhibits tumor growth in advanced solid tumors in phase I clinical trial
4. Research reveals how antibodies neutralize mosquito-borne virus
5. Genetically modified tobacco plants produce antibodies to treat rabies
6. NIH scientists identify protective role for antibodies in Ebola vaccine study
7. Scripps Research scientists devise powerful new method for finding therapeutic antibodies
8. Autoantibodies damage blood vessels in the brain
9. Antibodies for new rotavirus vaccines
10. Antibodies from rabbits reduce risks associated with unrelated donor stem cell transplantation
11. Antibodies from rabbits reduce risks associated with
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... February 23, 2017 , ... ... Justice jointly issued a letter to withdraw previous guidance issued by ... gender identity. The guidance issued in May 2016 by the Obama Administration came ...
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... ... outlet with a clinician-based audience, will be participating in Rare Disease Day events, ... Washington, D.C. In addition, Rare Disease Report, a website, weekly e-newsletter and quarterly ...
(Date:2/23/2017)... ... , ... Hamlin Dental Group and Dr. Hamid Reza, dentist in North ... month of February, patients who visit Hamlin Dental Group will receive a ticket for ... at the Cheesecake Factory. , Tickets are available for routine dental visits and ...
(Date:2/23/2017)... ... February 23, 2017 , ... On April 13, ... symposium on “Doping in Sport: How the Culture Might Change,” in ... LLP. The symposium will be held at Pepperdine University in Malibu, California. , ...
(Date:2/23/2017)... ... February 23, 2017 , ... ERT, a global data and ... Premier Research, a leading clinical development service provider, has selected ERT’s Trial Oversight ... due in part to an array of circumstances including the use of multiple ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... -- Genesis Healthcare Services has merged with Hospice Cloud, a ... Bill Monast , President and CEO of Hospice Cloud ... , executives with Home Health Depot, Inc., the parent ... This acquisition helps Hospice Cloud maintain its position as ... equipment (DME) solutions for the hospice industry. Nathan ...
(Date:2/23/2017)... , Feb. 23, 2017  Cogentix Medical, Inc. ... and markets innovative proprietary products for the urology market, ... fiscal year ended December 31, 2016 before the market ... The Company will host a conference call and webcast ... Thursday, March 9, 2017 at 11:00 a.m. Eastern Time ...
(Date:2/23/2017)... REDWOOD CITY, Calif., Feb. 23, 2017 Nevro Corp. ... innovative evidence-based solutions for the treatment of chronic pain, today ... ended December 31, 2016. 2016 Accomplishment & ... the full year 2016, an increase of 228% as reported, ... million for 2016, an increase of 612% over the prior ...
Breaking Medicine Technology: